In its early stages, prostate cancer usually causes no symptoms; when urinary discomfort, blood in the urine or semen, or bone pain develop, they may indicate a more advanced stage or another condition, such as benign prostatic hyperplasia (an enlarged prostate)1,2. That is why early diagnosis relies on prostate-specific antigen (PSA) testing, magnetic resonance imaging (MRI), and, when indicated, a biopsy3. Treatment depends on each tumor's risk category and is decided through a multidisciplinary approach.
How Does Prostate Cancer Start?
Prostate cancer begins when cells in the prostate gland acquire genetic alterations and begin to grow uncontrollably2,4. The most common type is adenocarcinoma, which develops from glandular cells and largely depends on male hormones (androgens) for its growth2,4. Many tumors grow slowly over years, while others are more aggressive; distinguishing between them is one of the primary goals of diagnosis1.
The main established risk factors are1,2:
- Age.
- A family history of prostate cancer.
- African ancestry.
- Inherited genetic mutations, such as those in the BRCA2 gene.
Benign prostatic hyperplasia and prostate cancer are separate conditions, although they can occur simultaneously.
Early Symptoms of Prostate Cancer
In most cases, early-stage prostate cancer causes no symptoms whatsoever1,2. This is why PSA screening is recommended based on age and individual risk, through shared decision-making with your doctor5.
As the tumor grows or spreads, symptoms may include1,2:
- Changes in urination: a weak stream, difficulty starting urination, urgency, or waking up frequently at night to urinate.
- Blood in the urine or semen.
- New-onset erectile dysfunction.
- Persistent bone pain, especially in the lower back, hips, or ribs.
- Unexplained weight loss or fatigue.
None of these symptoms are unique to prostate cancer: urinary changes are far more often caused by benign prostatic enlargement or infections. What matters most is having them evaluated by a urologist.
Diagnostic Options for Prostate Cancer in Guadalajara
The diagnostic pathway follows a structured approach aimed at identifying clinically significant tumors while avoiding unnecessary biopsies3,6:
- PSA and Risk Assessment. The PSA value is interpreted alongside your age, family history, and prostate size. For an initial elevated PSA reading, AUA/SUO guidelines recommend repeating the test before ordering further workups5.
- Physical Examination. A digital rectal exam (DRE) can complement PSA findings5.
- Multiparametric MRI (mpMRI). European guidelines (EAU) recommend an MRI before a biopsy to identify suspicious lesions and help determine whether a biopsy is truly necessary3.
- Prostate Biopsy. This is the definitive test that confirms the diagnosis and establishes the tumor grade (Gleason score or ISUP Grade Group)3.
- Staging Studies. In higher-risk tumors, advanced imaging studies, such as a PSMA PET scan, are used to evaluate whether the disease has spread3.
In Guadalajara, Dr. Manuel Alejandro González Ramírez, specialist in Urology, Endourology, and Robotic Surgery at CURO (Centro Urológico de Occidente), provides comprehensive diagnostic evaluations, including imaging protocols and transrectal, transperineal, and MRI-fusion prostate biopsies.
Prostate Biopsy: Transrectal, Transperineal, and Fusion
| Type | How It Is Performed | Advantages | Considerations |
|---|---|---|---|
| Transrectal | Tissue samples are taken through the rectal wall under ultrasound guidance | Widely used, well-established technique | Higher risk of infection than the transperineal approach; requires preventive antibiotics3 |
| Transperineal | Tissue samples are taken through the perineal skin (between the scrotum and the anus) | Recommended by EAU guidelines due to its significantly lower risk of infection3 | Requires local anesthesia or sedation |
| Fusion Biopsy | Pre-biopsy MRI images are merged with real-time ultrasound to guide needles directly into suspicious areas; can be performed transrectally or transperineally | Improves detection of clinically significant cancer and reduces the diagnosis of insignificant tumors3,6 | Requires a prior multiparametric MRI and specialized equipment |
In many cases, targeted samples of suspicious areas are combined with systematic sampling of the entire prostate gland, depending on MRI findings3.
Treatment Options Based on Risk
Once a diagnosis is confirmed, the tumor is stratified into risk categories based on PSA levels, biopsy grade, and clinical stage3. Treatment is chosen according to that risk, your age, overall health, and personal preferences, ideally through a multidisciplinary team including urology, radiation oncology, and medical oncology1,3.
| Option | Generally Considered For | What It Involves |
|---|---|---|
| Active Surveillance | Low-risk tumors and select favorable intermediate-risk tumors | Monitoring with PSA, MRI, and repeat biopsies; active treatment is initiated only if disease progresses3 |
| Radical Prostatectomy | Localized prostate cancer in surgical candidates | Surgical removal of the prostate and seminal vesicles via open, laparoscopic, or robotic approaches3 |
| Radiation Therapy | Localized or locally advanced cancer | External beam radiation or brachytherapy; in higher-risk tumors, often combined with hormone therapy3 |
| Hormone Therapy (ADT) | Advanced disease, or in combination with radiation therapy | Suppresses the effect of androgens on tumor growth1 |
Regarding prostatectomy, comparative studies have evaluated open, laparoscopic, and robotic approaches with respect to complication rates, recovery times, and functional outcomes7,8,9. The surgical approach is individualized for each patient. The primary known risks of surgery are urinary incontinence and erectile dysfunction, which are thoroughly discussed before making a decision3. Robotic surgery is performed using [PLATAFORMA_ROBÓTICA] at [HOSPITAL_ROBÓTICA].
When to See a Urologist
Seek immediate medical care at the emergency room if you experience:
- Complete inability to urinate (urinary retention).
- Heavy blood in your urine or blood clots.
- Fever or chills with painful urination, especially following a biopsy.
- Back pain accompanied by weakness in the legs or loss of bladder or bowel control.
Schedule a clinic consultation if you have received an elevated PSA result, have a family history of prostate cancer, or are experiencing any of the symptoms listed above.
What to Expect During Your Evaluation with Dr. Alejandro González in Guadalajara
During your consultation, Dr. Alejandro González will review your medical and family history, your symptoms, and any prior PSA or imaging results. Depending on your case, he may order a repeat PSA, a prostate MRI, or a biopsy, explaining in detail what each test involves. If prostate cancer is confirmed, all treatment options, benefits, and risks will be reviewed together so you can make an informed decision. Consultations take place at Centro Médico Puerta de Hierro Sur (Suite T23, 2nd Floor), in southern Guadalajara, serving patients from Guadalajara, Zapopan, and Tlajomulco.
Frequently Asked Questions
How can prostate cancer be detected without a biopsy?
PSA testing and multiparametric MRI help estimate the likelihood of clinically significant cancer and determine whether a biopsy is needed3,6. In select men with low suspicion and an MRI showing no suspicious lesions, avoiding a biopsy and maintaining close surveillance may be considered3. However, an MRI does not fully replace a biopsy: only tissue analysis can definitively confirm the diagnosis and establish the tumor grade.
Does prostate cancer always cause symptoms?
No. In its early stages, prostate cancer generally causes no symptoms at all1,2. When symptoms such as difficulty urinating, blood in the urine, or bone pain appear, they may be caused by more advanced disease or other benign conditions like an enlarged prostate. This is why you should not wait for symptoms before getting checked, especially if you are in the recommended screening age group or have a family history.
What is active surveillance?
Active surveillance is a management strategy for low-risk tumors where, instead of initiating immediate treatment, the cancer is carefully monitored with routine PSA tests, MRIs, and periodic biopsies3. It aims to avoid the potential side effects of surgery or radiation therapy for tumors that are unlikely to progress. If tests show signs of disease progression, curative treatment is offered3. It is not the same as doing nothing: it requires structured, consistent follow-up.
If you have received an elevated PSA result or a recent diagnosis, learn more about care for prostate cancer in Guadalajara. Treatment costs depend on the required diagnostic tests, technique, hospital, and your insurance coverage, and will be confirmed during your consultation; review our health insurance information. You can also explore our prostate checkup in Guadalajara and robotic urologic surgery in Guadalajara.
References
- Raychaudhuri, Lin, Montgomery. Prostate Cancer: A Review. JAMA. April 22, 2025.
- Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nature Reviews Disease Primers. February 4, 2021.
- Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2026 Update. Part I: Screening, Diagnosis, and Local Treatment With Curative Intent. European Urology. September 1, 2026.
- Almeeri, Awies, Constantinou. Prostate Cancer, Pathophysiology and Recent Developments in Management: A Narrative Review. Current Oncology Reports. November 2024.
- Wei JT, Barocas DA, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. American Urological Association; July 2023.
- Williams, McVey, Perera, et al. Modern Paradigms for Prostate Cancer Detection and Management. The Medical Journal of Australia. October 17, 2022.
- Robert, Blin, Bladou, et al. Comparative effectiveness of robot-assisted vs. open prostatectomy: a real-life nationwide study. World Journal of Urology. June 10, 2025.
- Carbonara, Srinath, Crocerossa, et al. Robot-assisted radical prostatectomy versus standard laparoscopic radical prostatectomy: an evidence-based analysis of comparative outcomes. World Journal of Urology. October 2021.
- Almajali, Zaitoun, Darwish, et al. Emerging Robotic Platforms in Radical Prostatectomy: A Comparative Systematic Review and Network Meta-Analysis. Journal of Endourology. December 2025.
